A Science Translational Medicine review suggests integrating dogs with naturally occurring cancers into studies of new drug therapeutics could result in better treatments for our four-legged friends while helping inform therapeutic ...
Feb 4, 2016
0
16
An interactive web portal developed by scientists at KAUST offers a platform for cancer researchers to interrogate how RNA splicing in noncoding parts of genes fuels the growth of different types of tumors.
May 26, 2022
0
54
A newly discovered inhibitor of a common cancer-causing protein operates selectively, reducing expression of genes that fuel rampant cell proliferation and alter the epigenome, according to a Northwestern Medicine study published ...
Jun 6, 2022
0
52
A novel therapeutic approach that combines human epidermal growth receptor factor 2 (HER2)-targeted therapies with the cholesterol-lowering drug lovastatin can reduce the number of cancer treatments required to prevent tumor ...
Oct 12, 2023
0
38
Targeted cancer drugs are widely used because of their ability to inhibit specific proteins involved in cancer development with fewer side effects compared to chemotherapy drugs. But targeted therapies can often inhibit other ...
Oct 16, 2023
0
27
When prostate cancer spreads, it most often spreads to bone. And while the 5-year survival rate for prostate cancer that has not spread is nearly 100 percent, once the disease reaches bone, the 5-year survival rate is only ...
Dec 2, 2019
0
2
(HealthDay)—The first personalized treatment for patients with metastatic bladder cancer and susceptible fibroblast growth factor receptor (FGFR) genetic alterations was granted accelerated approval by the U.S. Food and ...
Apr 15, 2019
0
1
It may be possible to restore drug-resistant neuroendocrine prostate cancer to a state that responds to treatment by depletion of a certain protein in cancer cells. A recent study published in Communications Biology by the ...
Feb 2, 2024
0
8
Cancer Research UK is collaborating with Aleta Biotherapeutics (Aleta) to trial a new therapy that 'reboots' a treatment for some people with blood cancer whose cancer starts to come back.
Jun 25, 2021
0
0
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called AccurinsTM, announced today the presentation of late-breaker clinical data for BIND-014, ...
Apr 4, 2012
0
0
